Floatz logo

Gly-Low

Inflammation

Hoskinson Health and Wellness ClinicEarly Phase 1Active
CC
41/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
81/ 100

Competitive context

29 Active assets in the Inflammation cohort.

Asset / SponsorPhaseRating
Vildagliptin
Rio de Janeiro State University
Phase 4BB
PITAVASTATIN
Aichi Gakuin University
Phase 4BB
METHOXY POLYETHYLENE GLYCOL-EPOETIN BETA
Taipei Veterans General Hospital, Taiwan
Phase 4BB
Sitagliptin
University of Southern California
Phase 3BB
SUFENTANYL
The First Affiliated Hospital with Nanjing Medical University
Phase 4BB

View all 50 →

Same molecule, other indications

Gly-Low is also rated in:

obesity disorderDormant
CC
Indicative ·
45 / 100
View asset →
Physical DisabilityDormant
CC
Indicative ·
43 / 100
View asset →
Hormone DeficiencyDormant
CC
Indicative ·
43 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →